Therapeutic Targeting of Autoreactive B Cells: Why, How, and When?
B lymphocytes play critical roles in the development of autoimmunity, acting as autoantibody manufacturers, antigen-presenting cells, and producers of cytokines. Pan-B cell depletion has demonstrated efficacy in treatment of many autoimmune disorders, but carries with it an unfavorable safety profil...
Main Authors: | Zachary C. Stensland, John C. Cambier, Mia J. Smith |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/1/83 |
Similar Items
-
Enrichment and Detection of Antigen-Binding B Cells for Mass Cytometry
by: Zachary C. Stensland, et al.
Published: (2021-06-01) -
Application of single-cell RNA sequencing methods to develop B cell targeted treatments for autoimmunity
by: Catherine A. Nicholas, et al.
Published: (2023-07-01) -
Multilayer Control of B Cell Activation by the B Cell Antigen Receptor: Following Themes Initiated With Bill Paul
by: Anthony L. DeFranco
Published: (2018-04-01) -
Interference of B lymphocyte tolerance by prolactin in rheumatic autoimmune diseases
by: Mohammad Javad Mousavi, et al.
Published: (2023-06-01) -
B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells
by: Carlo G. Bonasia, et al.
Published: (2021-05-01)